Cohort 4 data demonstrated positive safety and efficacy results, including additional clinical benefit observed following ...

Why the latest soquelitinib data matters for Corvus Pharmaceuticals (CRVS) Corvus Pharmaceuticals (CRVS) just reported positive cohort 4 Phase 1 data for soquelitinib in moderate to severe atopic ...

Early eczema trial success and heavy trading are rapidly reshaping how investors view this drug developer, today, Jan. 20, ...

Corvus Pharma reports encouraging data for its eczema drug soquelitinib, showing strong skin improvement and no serious ...

Corvus Pharma (CRVS) stock surges as the company plans a Phase 2 trial for its lead asset against eczema following ...

Preclinical in vivo efficacy data in atopic dermatitis extend previous PoC in allergic asthmaPositive opinion from the ...

Shares of Corvus Pharmaceuticals rose after its investigational drug soquelitinib showed positive results in an early-stage trial in atopic dermatitis patients. The stock surged 50% to $12.10 in ...

A study published in Nutrition Reviews in November 2025 found evidence linking oral probiotics and synbiotics to improvements in atopic dermatitis (AD) symptoms. However, research for other skin ...

Investing.com -- Corvus Pharmaceuticals (NASDAQ:CRVS) stock surged 48% Tuesday morning following the company’s announcement ...

The company announced a $150 million public stock offering, including common shares and pre-funded warrants. ・Proceeds are ...

Corvus Pharmaceuticals soars on promising Phase 1 data for soquelitinib. But CRVS shares may not be able to sustain today's ...

Corvus Pharmaceuticals (NASDAQ:CRVS) shares surged 48% on Tuesday after the company released positive findings from a Phase 1 clinical study of its oral drug candidate soquelitinib in atopic ...